Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V-6 Immunitor
- Development stage
- Unknown
- Lead developer
- Immunitor
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
V-6 Immunitor is an orally administered therapeutic vaccine developed by Immunitor for the treatment of atherosclerosis and obesity. It is a tableted preparation containing pooled antigens derived from porcine adipose tissue. The vaccine is designed to modulate the inflammatory response associated with metabolic diseases and atherogenesis. Clinical trial results have demonstrated that V-6 is safe and can lead to significant increases in HDL cholesterol levels and reductions in body fat indices, such as waist, mid-arm, and thigh circumferences, without necessarily changing overall body weight or BMI. It is positioned as an anti-atherogenic immune intervention.
- Other names
- V6V-6V 6
Beyond the preview
Go deeper on V-6 Immunitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V-6 Immunitor.